HEART UK March HCP e-Newsletter


NICE FH Guidelines 
Public registration facility to observe the committee meeting for Familial hypercholesterolaemia is open on the NICE website. As yet, no date has been announced for a revised consultation period - more info here.
Repatha® (Evolocumab) Receives European Commission Approval For New 420 mg Single-Dose Delivery Option
The European Commission (EC) has adopted a decision to change the Repatha (evolocumab) marketing authorization to approve a new single-dose delivery option. More info here.
New Phase 3 Praluent® (alirocumab) Injection Clinical Trial Analyses
Sanofi will present key data at the American Cardiovascular Conference on 17thMarch, including presentations on the effects of Praluent across several patient subsets such as diabetes, heterozygous familial hypercholesterolemia (HeFH), and atherosclerotic cardiovascular disease (ASCVD) and post-hoc analyses on the effect of Praluent on major cardiovascular events (MACE). More info here.
Positive Results from Pivotal Study of Volanesorsen in Patients with Familial Chylomicronemia Syndrome (FCS)
Akcea announces Phase 3 APPROACH study of volanesorsen and reports it met its primary endpoint of reducing triglyceride levels in patients with familial chylomicronemia syndrome (FCS). More info here.
Latest NICE Quality standard [QS144]: Care of dying adults in the last days of life
This quality standard from NICE covers the clinical care of adults (aged 18 and over) who are dying, during the last 2 to 3 days of life. It describes high-quality care in priority areas for improvement. More info here.
Salt Awareness Week
Resources are now available to pre-order here. (If you have ordered posters and leaflets for Salt Awareness Week, these will be posted out w/c 13th March). More infohere.


Hepatotoxicity of Statins and Other Lipid-lowering Agents
A review covering the current knowledge on the hepatotoxicity associated with statins and other lipid lowering drugs published in Liver International. More info here.
Scotland study to probe causes of rare diseases
People in Scotland with rare genetic diseases are set to benefit from a DNA study that seeks to improve their diagnoses and treatments. More info here.
Non-HDL-C a better predictor of mortality than LDL-C
Usefulness of Non-High Density Lipoprotein Cholesterol as a Predictor of Cardiovascular Disease Mortality in Men in 22 Year Follow Up. More info here.
PCSK9 inhibitor increases the removal of LDL and Lp(a) from the circulation via LDL-receptors
Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans. More info here.
Do low vitamin D levels increase the risk for myalgia in patients who are taking statins?
The mechanism for statin-related myalgia is not fully understood, but vitamin D has been speculated to play a role. Philip J. Gregory, PharmD explores this further in an article in Medscape (free subscription). More info here.
Midlife cholesterol levels predict Alzheimer disease with ASCVD
A study with a long-term follow-up, demonstrating pure AD (without ASCVD) was not associated with cholesterol levels, blood pressure, glucose tolerance of diabetes, whereas AD with ASCVD was significantly associated with midlife cholesterol levels. More info here.
Few adverse events of very low LDL-C levels with PCSK9 antibody 
Analysis of data from 14 randomised controlled alirocumab studies with 5,234 patients treated for up to 2 years were pooled, in order to evaluate the occurrence of adverse events and laboratory values in patients who achieved 2 or more consecutive calculated LDL-C values below 25 or 15 mg/dl. More info here.
Long-term treatment of patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study
Assessment of the long-term safety and efficacy of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab in a subset of patients with homozygous familial hypercholesterolaemia enrolled in an open-label, non-randomised phase 3 trial. More info here.
Limitations of cholesterol lowering with PCSK9 inhibitors
Article in The Lancet by Gilbert Thompson (pay for access). More info here.
Evidence-based goals in LDL-C reduction
The evidence from trials of statin therapy suggests that benefits in cardiovascular disease (CVD) event reduction are proportional to the magnitude of low-density lipoprotein cholesterol (LDL-C) lowering. The lack of a threshold at which LDL-C lowering is not beneficial, in terms of CVD prevention observed in these trials, is supported by epidemiological and genetic studies reporting the cardio-protective effects of lifelong low exposure to atherogenic cholesterol in a graded fashion. More info here.
Lipoprotein apheresis is essential for managing pregnancies in patients with homozygous familial hypercholesterolemia: Seven case series and discussion
For patients with homozygous familial hypercholesterolemia (HoFH), atherogenic lipoprotein changes and increased stress on cardiovascular system during pregnancy may pose substantial risk for both the mother and her fetus. Although lipoprotein apheresis (LA) is reported as the most effective therapy to control LDL-C levels during pregnancy in HoFH patients, only case reports have been published, and there is no guidance for management. More info here.
Myotoxicity of statins: Mechanism of action
A study suggesting statin-related side effects, low dose, and poor adherence—rather than psychosocial or socioeconomic factors—are barriers to LDL-cholesterol (LDL-C) control in patients prescribed a statin after a coronary hospitalisation. More info here.
Molecular basis of familial hypercholesterolemia
The phenotype of familial hypercholesterolemia is caused by more than 1700 mutations the LDLR, apoB and PCSK9 genes, which explains approximately 85% of familial hypercholesterolemia cases. By means of next-generation sequencing, an increasing number of mutations in established and putative novel genes associated with this phenotype have been identified. (Pay for access). More info here.
Statins, haemostatic factors and thrombotic risk
A review aiming to provide an update on the impact of statin treatment on markers of haemostasis and platelet function and on thrombosis-related outcomes. (Pay for access). More info here.


The ACCEA Excellence Awards 2017 opens on Monday 28 February 2017

The Advisory Committee on Clinical Excellence Awards (ACCEA) recognises HEART UK as a registered specialist society which enables HEART UK to support nominations at bronze, silver and gold level. There is still time for HEART UK to consider your application in its ranking and citation process. Send your completed application to Jane Kendrick at by Monday 27 March 2017. Full application details can be found on our website.

The Rianna Wingett Award : Beyond the Call of Duty for FH 

Patients are invited to nominate a health care professionals that has gone beyond the call of duty in terms of early detection of FH or raised cholesterol or championed new ideas on screening for FH.



Applications are invited to submit abstracts at the HEART UK conference on any topic relating to cholesterol and related conditions. The deadline for abstract applications is Friday 10 March

A limited number of travel grants are available for health care professionals. The deadline for travel grant applications is 7 April.

Other Events:

Saturday 22 April - The LPLD Alliance Patient Advisory Meeting on behalf of Akcea Therapeutics at Crowne Plaza, Birmingham City Centre, Central Square. To book a place and more information email Jill Prawer
Sunday 23 - Wed 26 April, 2017 - 85th EAS Congress at Prague Congress Centre, 5. května 65, 140 21 Prague 4, Czech Republic
Friday 28 April 2017 - British Journal of Cardiology Healthcare Forum - inaugural meeting
Monday 15 - Wednesday 17 May 2017 - The 6th ICCR Congress at the Hotel Le Concorde Quebec, Quebec City, Canada
Friday 10 - Saturday 11 November 2017 - Issues & Answers in Cardiovascular Disease, EMCC Nottingham UK


Learning Zone
The HEART UK LearningZone includes a full range of education resources including CPD accredited papers, Diploma and MSc. The training modules have been developed with the RCGP, PCCJ and others with all contributing towards professional development including Diploma MSc who produce an awarding-winning online postgraduate course for health professionals.

Professional Grants
HEART UK provide a number of annual grants up to £3,000 each, annually for a maximum of 3 years for any one grant. The purpose is to stimulate interest and activity in the medical profession, patients and members of the public in projects which will help achieve the objectives of the charity. 

Professional Membership

Become a Professional Member
HEART UK is the only charity dedicated to supporting health care professionals managing people with raised cholesterol and other lipid conditions. Working in partnership with HEART UK, you will help us make a difference and, in turn, we can help contribute to the growth and development of your professional career.